FDA Approves nivolumab for wild-type advanced melanoma

24 Nov 2015 11:02 AM | Lori Aubrey (Administrator)

The U.S. Food and Drug Administration (FDA) approved the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) as a single agent for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.



Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948

This website brought to you by:

Powered by Wild Apricot Membership Software